RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Rating of “Hold” from Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $4.00.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Stock Performance

Shares of RAPT Therapeutics stock opened at $0.79 on Monday. The company’s 50 day moving average price is $1.12 and its 200-day moving average price is $1.36. RAPT Therapeutics has a 52-week low of $0.75 and a 52-week high of $8.58. The stock has a market capitalization of $104.35 million, a price-to-earnings ratio of -0.29 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). As a group, equities research analysts forecast that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Several large investors have recently bought and sold shares of the company. Medicxi Ventures Management Jersey Ltd bought a new position in shares of RAPT Therapeutics in the 4th quarter worth approximately $35,316,000. TCG Crossover Management LLC bought a new position in RAPT Therapeutics in the fourth quarter worth $19,751,000. Orbimed Advisors LLC bought a new position in RAPT Therapeutics in the fourth quarter worth $20,754,000. Foresite Capital Management VI LLC purchased a new position in RAPT Therapeutics during the fourth quarter valued at $19,750,000. Finally, RTW Investments LP bought a new stake in shares of RAPT Therapeutics during the 4th quarter valued at $18,587,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.